🇺🇸 SECGSK plcDoubao · 实盘不做把握 7/10不做原因:已被定价
北京时间·🕒 发布 18:32:38·⟳ 抓取 18:33:01 +23s·⚡ 决策 10-26 18:35:02 +2m01s·21.2 小时前
GSK 6-K 仅为转载 10 月 23 日已发布的 Mo-Rez 卵巢癌 Ib 期阳性更新，数据已在 ESMO 消化，GSK 与翰森制药均无新增 edge
6-K 只是对 10 月 23 日公司新闻稿的行政性转载，核心数据是 4 月 SGO 初始数据后的更长随访更新、且 III 期项目早已启动，不构成新的基本面增量；消息已在 ESMO 窗口公开三个交易日，翰森制药提前大涨后周一收平、GSK 周一盘前基本持平，说明已被消化。对千亿美元级 GSK 弹性不足，对翰森的里程碑/分成量级亦无法在短期兑现，风险收益不支持追入。
📄 原文GSK plc↗ 原文
----- a3306a.htm ----- 6-K 1 a3306a.htm POSITIVE MO-REZ PHASE IB DATA IN OVARIAN CANCER a3306a UNITED STATES SECURITIES…
不做 GSK plc（GSK.US）
6-K 转载 10 月 23 日已首发的 Ib 期随访更新，无新增事实；单一早期资产对约 1,017 亿美元市值弹性小，周一盘前仅 +0.16% 确认已 price-in，无交易 edge。
不做 翰森制药（03692.HK）
虽为 Mo-Rez 授权方且数据正面，但消息 10 月 23 日已公开、股价 10 月 20 日已 +8.32% 抢跑，10 月 26 日收平；里程碑/分成短期不兑现，港股盘后追入无预期差。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Mo-Rez Ib 期更新数据积极但属旧闻随访：新闻稿 10 月 23 日首发并在 ESMO 报告，10 月 26 日 6-K 无新增内容；GSK 盘前持平、翰森制药事件前已 +8.3% 后当日收平，预期差已闭合，两个候选均 AVOID。
🔎 新鲜度:最早出现 2026-10-23 · 扩散 high · price-in 风险 high ↗
关键理由
- 数据本身积极（cORR 62%、DoR 12.2 个月、PFS 11.1 个月、安全性可控），验证 B7-H4 ADC 在铂耐药卵巢癌的潜力，方向利好 GSK 及授权方翰森制药。
- 但该利好 10 月 23 日已由公司一手发布并在 ESMO 公开，6-K 仅为滞后备案，翰森已提前大涨、GSK 与翰森周一均无正向跳空，本次信号无未定价增量。
主要风险
- Ib 期样本仅 45 例，≥3 级 TRAE 达 71%、血液学毒性及剂量调整比例高（中断 51%、减量 47%），III 期存在疗效或安全性不能复制的风险。
- 若 ESMO 现场或后续券商上调 Mo-Rez 销售峰值预测，可能带来二段重定价；但这属于新信息，当前信号不支持提前埋伏。
反向证据
- 做多前查反向 · 来源 filing · 日期 2026-10-23 · 影响 weakens
≥3 级治疗相关不良事件 71%、剂量中断 51%、减量 47%，血液学毒性突出；Ib 期仅 45 例，III 期复制风险构成多头逻辑的实质反证。
检索:Mo-Rez BEHOLD-1 safety TRAE ILD phase III risk 原文 ↗ - 做多前查反向 · 来源 filing · 日期 2026-04 · 影响 weakens
公告引用 Oaknin 等 2026 年 4 月 SGO 首次公布的 BEHOLD-1 结果，本次仅为更长随访（>13 个月）更新，并非首次人体疗效披露，边际信息量有限。
检索:mocertatug rezetecan initial data SGO 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:不进入 ENTER，GSK 与翰森均给 AVOID；未构造历史先例面板，因为即使同类事件历史上上涨，也无法改变本条信号已无增量的事实。
方向:数据方向为正面，但本次结论不依赖先例涨幅：信号本身是滞后三天的行政性备案且盘面已确认无重定价。
涨幅量级:未以先例校准幅度，因为不存在对新催化的可交易窗口。
形态:Ib 期数据在大型肿瘤会议（ESMO/ASCO）前抢跑、会议落地后 sell-the-news 是生物医药常见模式；翰森事件前 +8.3% 而会议窗口收平与该模式一致。
工具执行结果 · 成功 2 · 降级 2 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 249 ms
{"result": "search_processed_events:agent query=`gsk behold-1 esmo 2026 b7-h4 adc 62% orr | gsk mo-rez mocertatug rezetecan ovarian cancer phase ib | 翰森制药 hansoh mocertatug rezetecan gsk license`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 68.3/72 小时、2497 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是 - stock_quote 降级 stock_tools HTTP · 89 ms
{ - stock_quote 降级 stock_tools HTTP · 1,159 ms
{ - web_search 成功 doubao_search · 2,719 ms
web_search「GSK mocertatug rezetecan Mo-Rez BEHOLD-1 ESMO 2026 ovarian cancer data shares reaction」无结果。
原文全文
展开原文 · 11,829 字
----- a3306a.htm -----
6-K
1
a3306a.htm
POSITIVE MO-REZ PHASE IB DATA IN OVARIAN CANCER
a3306a
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 23 October 2026, London UK
GSK presents positive data for Mo-Rez in platinum-resistant ovarian
cancer
●
62%
confirmed objective response rate and 12.2-month median duration of
response in phase Ib trial
●
11.1-month
median progression-free survival in a difficult-to-treat
setting
●
Five
pivotal phase III studies now underway across gynaecological
cancers
GSK plc (LSE/NYSE: GSK) today announced updated data from the
global phase I BEHOLD-1 trial for mocertatug rezetecan (Mo-Rez), an
investigational B7-H4-targeted antibody-drug conjugate (ADC).
Results showed clinically meaningful and durable responses at
>13 months follow-up, building on initial data in
platinum-resistant ovarian cancer (PROC) announced earlier this
year. These data will be presented in a late-breaking oral session
at the European Society for Medical Oncology (ESMO) Congress 2026
in Madrid, Spain.
[1]
Mo-Rez achieved a confirmed objective response rate (cORR)
of 62% (n=28/45; 95% confidence interval [CI]:
46.5-76.2%), with a median duration of response (DoR) of 12.2
months (95% CI: 7.0-12.7) at the selected phase III dose of 5.8
mg/kg. Median progression-free survival (PFS) was 11.1 months (95%
CI: 8.3-13.9).
1
Hesham Abdullah, Senior Vice President, Global Head Oncology,
R&D, GSK
, said:
“Current treatment options for patients with
platinum-resistant ovarian cancer are limited and achieving durable
responses remains a challenge. These promising results for Mo-Rez
show that treatment responses and durability are maintained over
time in many patients, alongside encouraging progression-free
survival and a manageable safety profile. We have accelerated the
phase III development programme across gynaecological cancers, with
five pivotal studies now underway.”
Safety results remain consistent with previously published
data.
[2]
Grade ≥3 treatment-related
adverse events (TRAEs) were observed in 71% (n=32/45) of
patients and were predominantly haematologic. At the selected phase
III dose, TRAEs led to treatment discontinuation
in 2% (n=1/45) of patients treated and interstitial lung
disease (ILD)/pneumonitis occurred in 2% (n=1/45) of
patients.
1
Vanda Salutari, Study Investigator for BEHOLD-1, Innovative
Therapies Unit for Female Cancers, Department of Women and Child
Health, Fondazione Policlinico Universitario Agostino Gemelli
IRCCS, Rome, Italy
said:
“Despite advances in ovarian cancer, platinum-resistant
disease is one of the hardest to treat, and many patients still
experience limited benefit from available treatment options. The
duration of response and progression-free survival observed in
BEHOLD-1 are particularly encouraging relative to what is typically
seen in this setting where prolonged disease control remains
difficult to achieve.”
B7-H4 is an immune checkpoint that is widely expressed in
gynaecological cancers and is low in normal tissues. The
responses to Mo-Rez observed across a range of B7-H4 expression
levels support its broad potential in gynaecological cancers and an
accelerated large-scale phase III programme is now underway in
ovarian and endometrial cancers.
Additional data from the BEHOLD programme being presented at ESMO
include an exploratory biomarker analysis from BEHOLD-1 showing
responses across a range of B7-H4 expression levels and study
designs for the phase III BEHOLD-Ovarian01 and BEHOLD-Endometrial01
studies.
[3]
,
[4]
,
[5]
The BEHOLD-1 results support the
selected 5.8 mg/kg dose being evaluated in the phase III
development programme.
About the BEHOLD clinical trial programme
The BEHOLD clinical programme is GSK’s global development
plan that includes the BEHOLD-1 (NCT06431594) monotherapy study and
the ongoing BEHOLD-2 (NCT06796907) combination
study.
Five pivotal phase III trials are currently underway:
●
Platinum-resistant
ovarian cancer (BEHOLD-Ovarian01 / NCT07286266)
●
Platinum-sensitive
ovarian cancer (BEHOLD-Ovarian02 / NCT07684612)
●
First-line
maintenance setting for ovarian cancer without homologous
recombination deficiency (BEHOLD-Ovarian03 /
NCT07694427)
●
Second-line
advanced and recurrent endometrial cancer (BEHOLD-Endometrial01 /
NCT07286331)
●
First-line
maintenance setting mismatch repair proficient endometrial cancer
(BEHOLD-Endometrial02 / NCT07684599).
About BEHOLD-1
The BEHOLD-1 clinical trial is a two-part, open-label, phase I
study evaluating the safety, tolerability and efficacy of Mo-Rez
injection in patients with platinum-resistant ovarian cancer (PROC)
or advanced/recurrent endometrial cancer (EC). Phase Ia assessed up
to four Mo-Rez dose levels in patients with advanced solid tumours,
with intravenous administration every three weeks until progression
or toxicity. In the phase Ib dose expansion, patients with PROC or
EC (1-3 prior lines of therapy) were randomised to three or two
Mo-Rez dose levels, respectively.
At data cut-off, a total of 136 PROC patients were enrolled in
BEHOLD-1. At the selected phase III dose evaluated in phase Ib, the
most common adverse events in PROC were gastrointestinal and
haematological, consistent with treatments in this class.
Treatment-related adverse events led to dose interruptions in 51%
of patients with PROC and dose reductions in 47%. Primary endpoints
included: incidence of dose-limiting toxicity in phase Ia and
confirmed objective response rate (cORR) by investigator per RECIST
1.1 in phase Ib. Patients with EC treated at the selected phase III
dose continue to be followed, with data expected to be presented in
the future.
About mocertatug rezetecan
Mo-Rez is a novel investigational B7-H4-targeted antibody-drug
conjugate designed to optimise efficacy and tolerability. It is
composed of a fully human anti-B7-H4 monoclonal antibody covalently
linked to a topoisomerase inhibitor payload and has a
drug-to-antibody ratio (DAR) of 6. GSK acquired exclusive worldwide
rights (excluding mainland China, Hong Kong, Macau and Taiwan) from
Hansoh Pharma to progress clinical development and
commercialisation of Mo-Rez globally.
About ovarian cancer
Ovarian cancer affects 843,000 people with 240,000 new cases
annually.
[6]
70%
of people living with ovarian cancer will present with advanced
disease and survival usually declines after
recurrence.
[7]
,
[8]
Patients
with platinum-resistant ovarian cancer (PROC), one of the hardest
to treat, face limited treatment options and poor
outcomes.
[9]
Many will develop resistance to
platinum-based chemotherapy, the backbone of first-line treatment,
underscoring the need for innovations that can deliver meaningful
benefit.
9
GSK in oncology
GSK is focused on developing differentiated medicines for cancers
where patients continue to face poor outcomes, treatment
resistance, limited options or significant treatment burden. We
focus where advances in science and technology offer the greatest
opportunity to improve outcomes across haematological, lung,
gastrointestinal, genitourinary and gynaecological cancers. Across
multiple modalities, including targeted small molecules,
antibody-drug conjugates (ADCs) and immunotherapies, GSK applies
deep expertise in cancer biology and immune system science to
develop differentiated medicines designed to deliver durable
responses, overcome resistance and reduce treatment
burden.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at
www.gsk.com
.
GSK enquiries
Media:
Tim
Foley
+44 (0)
20 8047 5502
(London)
Sarah
Clements
+44 (0)
20 8047 5502
(London)
Madison
Goring
+44 (0)
20 8047 5502
(London)
Kathleen
Quinn
+1 202
603 5003
(Washington
DC)
Alison
Hunt
+1 540
742 3391
(Washington
DC)
Investor
Relations:
James
Dodwell
+44 (0)
7881 269066
(London)
Mick
Readey
+44 (0)
7990 339653
(London)
Joanna
Tuplin
+44 (0)
7788 351650
(London)
Sam
Piper
+44 (0)
7824 525779
(London)
Dan
Smith
+44 (0)
7823 523885
(London)
Jeff
McLaughlin
+1 215
751 7002
(Philadelphia)
Frannie
DeFranco
+1 215
751 3126
(Philadelphia)
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the “Risk
Factors” section in GSK’s Annual Report on Form 20-F
for 2025, and GSK’s Q2 Results for 2026.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
References
[1]
Salutari V. Mocertatug rezetecan
(Mo-Rez) in patients with platinum-resistant ovarian cancer (PROC):
Updated results with longer follow-up from the global BEHOLD-1
study. Presented at the European Society for Medical Oncology
(ESMO) Congress 2026. October 2026.
[2]
Oaknin A, McKean W, van Dongen M, et
al. Mocertatug rezetecan (GSK5733584), a B7-H4 targeted antibody
drug conjugate, in platinum-resistant ovarian cancer and
endometrial cancer: First results from the global BEHOLD-1 study.
Presented at the Society of Gynecologic Oncology (SGO) Annual
Meeting on Women’s Cancer 2026. April
2026.
[3]
Lheureux S. BEHOLD-1: Exploratory
analysis of biomarkers associated with mocertatug rezetecan
(Mo-Rez) response in patients with platinum-resistant ovarian
cancer (PROC). Presented at the European Society for Medical
Oncology (ESMO) Congress 2026. October 2026.
[4]
Backes F. BEHOLD-Ovarian01: A Phase 3
randomised trial to evaluate mocertatug rezetecan (Mo-Rez) versus
standard of care (SoC) in patients (pts) with platinum-resistant
ovarian cancer (PROC). Presented at the European Society for
Medical Oncology (ESMO) Congress 2026. October
2026.
[5]
Oaknin A. BEHOLD-Endometrial01: A
randomised Phase 3 study evaluating the efficacy and safety of
mocertatug rezetecan (Mo-Rez) versus chemotherapy in patients with
advanced or recurrent endometrial cancer after platinum-based
therapy and immunotherapy. Presented at the European Society for
Medical Oncology (ESMO) Congress 2026. October
2026.
[6]
Ren Y, Xu R, Wang Y, et al. Global,
regional, and national burden of ovarian cancer in women aged
45 + from 1990 to 2021 and projections for 2050: a
systematic analysis based on the 2021 global burden of disease
study. J Cancer Res Clin Oncol.
2025;151(8):225.
[7]
Rauh-Hain JA, Krivak TC, Del Carmen
MG, Olawaiye AB. Ovarian cancer screening and early detection in
the general population. Rev Obstet Gynecol.
2011;4(1):15-21.
[8]
Salas Bolívar P, Gonzalez-Benitez
C, Carbonell López M, et al. Prognostic factors after the
first recurrence of ovarian cancer. Journal of Clinical Medicine.
2025;14(2):470.
[9]
Eskander RN, Moore KN, Monk BJ, et al.
Overcoming the challenges of drug development in platinum-resistant
ovarian cancer. Front Oncol. 2023;13:1258228.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
GSK plc
(Registrant)
Date: October
26, 2026
By:/s/ VICTORIA
WHYTE
--------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GSK plc
6-K
1
a3306a.htm
POSITIVE MO-REZ PHASE IB DATA IN OVARIAN CANCER
a3306a
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 23 October 2026, London UK
GSK presents positive data for Mo-Rez in platinum-resistant ovarian
cancer
●
62%
confirmed objective response rate and 12.2-month median duration of
response in phase Ib trial
●
11.1-month
median progression-free survival in a difficult-to-treat
setting
●
Five
pivotal phase III studies now underway across gynaecological
cancers
GSK plc (LSE/NYSE: GSK) today announced updated data from the
global phase I BEHOLD-1 trial for mocertatug rezetecan (Mo-Rez), an
investigational B7-H4-targeted antibody-drug conjugate (ADC).
Results showed clinically meaningful and durable responses at
>13 months follow-up, building on initial data in
platinum-resistant ovarian cancer (PROC) announced earlier this
year. These data will be presented in a late-breaking oral session
at the European Society for Medical Oncology (ESMO) Congress 2026
in Madrid, Spain.
[1]
Mo-Rez achieved a confirmed objective response rate (cORR)
of 62% (n=28/45; 95% confidence interval [CI]:
46.5-76.2%), with a median duration of response (DoR) of 12.2
months (95% CI: 7.0-12.7) at the selected phase III dose of 5.8
mg/kg. Median progression-free survival (PFS) was 11.1 months (95%
CI: 8.3-13.9).
1
Hesham Abdullah, Senior Vice President, Global Head Oncology,
R&D, GSK
, said:
“Current treatment options for patients with
platinum-resistant ovarian cancer are limited and achieving durable
responses remains a challenge. These promising results for Mo-Rez
show that treatment responses and durability are maintained over
time in many patients, alongside encouraging progression-free
survival and a manageable safety profile. We have accelerated the
phase III development programme across gynaecological cancers, with
five pivotal studies now underway.”
Safety results remain consistent with previously published
data.
[2]
Grade ≥3 treatment-related
adverse events (TRAEs) were observed in 71% (n=32/45) of
patients and were predominantly haematologic. At the selected phase
III dose, TRAEs led to treatment discontinuation
in 2% (n=1/45) of patients treated and interstitial lung
disease (ILD)/pneumonitis occurred in 2% (n=1/45) of
patients.
1
Vanda Salutari, Study Investigator for BEHOLD-1, Innovative
Therapies Unit for Female Cancers, Department of Women and Child
Health, Fondazione Policlinico Universitario Agostino Gemelli
IRCCS, Rome, Italy
said:
“Despite advances in ovarian cancer, platinum-resistant
disease is one of the hardest to treat, and many patients still
experience limited benefit from available treatment options. The
duration of response and progression-free survival observed in
BEHOLD-1 are particularly encouraging relative to what is typically
seen in this setting where prolonged disease control remains
difficult to achieve.”
B7-H4 is an immune checkpoint that is widely expressed in
gynaecological cancers and is low in normal tissues. The
responses to Mo-Rez observed across a range of B7-H4 expression
levels support its broad potential in gynaecological cancers and an
accelerated large-scale phase III programme is now underway in
ovarian and endometrial cancers.
Additional data from the BEHOLD programme being presented at ESMO
include an exploratory biomarker analysis from BEHOLD-1 showing
responses across a range of B7-H4 expression levels and study
designs for the phase III BEHOLD-Ovarian01 and BEHOLD-Endometrial01
studies.
[3]
,
[4]
,
[5]
The BEHOLD-1 results support the
selected 5.8 mg/kg dose being evaluated in the phase III
development programme.
About the BEHOLD clinical trial programme
The BEHOLD clinical programme is GSK’s global development
plan that includes the BEHOLD-1 (NCT06431594) monotherapy study and
the ongoing BEHOLD-2 (NCT06796907) combination
study.
Five pivotal phase III trials are currently underway:
●
Platinum-resistant
ovarian cancer (BEHOLD-Ovarian01 / NCT07286266)
●
Platinum-sensitive
ovarian cancer (BEHOLD-Ovarian02 / NCT07684612)
●
First-line
maintenance setting for ovarian cancer without homologous
recombination deficiency (BEHOLD-Ovarian03 /
NCT07694427)
●
Second-line
advanced and recurrent endometrial cancer (BEHOLD-Endometrial01 /
NCT07286331)
●
First-line
maintenance setting mismatch repair proficient endometrial cancer
(BEHOLD-Endometrial02 / NCT07684599).
About BEHOLD-1
The BEHOLD-1 clinical trial is a two-part, open-label, phase I
study evaluating the safety, tolerability and efficacy of Mo-Rez
injection in patients with platinum-resistant ovarian cancer (PROC)
or advanced/recurrent endometrial cancer (EC). Phase Ia assessed up
to four Mo-Rez dose levels in patients with advanced solid tumours,
with intravenous administration every three weeks until progression
or toxicity. In the phase Ib dose expansion, patients with PROC or
EC (1-3 prior lines of therapy) were randomised to three or two
Mo-Rez dose levels, respectively.
At data cut-off, a total of 136 PROC patients were enrolled in
BEHOLD-1. At the selected phase III dose evaluated in phase Ib, the
most common adverse events in PROC were gastrointestinal and
haematological, consistent with treatments in this class.
Treatment-related adverse events led to dose interruptions in 51%
of patients with PROC and dose reductions in 47%. Primary endpoints
included: incidence of dose-limiting toxicity in phase Ia and
confirmed objective response rate (cORR) by investigator per RECIST
1.1 in phase Ib. Patients with EC treated at the selected phase III
dose continue to be followed, with data expected to be presented in
the future.
About mocertatug rezetecan
Mo-Rez is a novel investigational B7-H4-targeted antibody-drug
conjugate designed to optimise efficacy and tolerability. It is
composed of a fully human anti-B7-H4 monoclonal antibody covalently
linked to a topoisomerase inhibitor payload and has a
drug-to-antibody ratio (DAR) of 6. GSK acquired exclusive worldwide
rights (excluding mainland China, Hong Kong, Macau and Taiwan) from
Hansoh Pharma to progress clinical development and
commercialisation of Mo-Rez globally.
About ovarian cancer
Ovarian cancer affects 843,000 people with 240,000 new cases
annually.
[6]
70%
of people living with ovarian cancer will present with advanced
disease and survival usually declines after
recurrence.
[7]
,
[8]
Patients
with platinum-resistant ovarian cancer (PROC), one of the hardest
to treat, face limited treatment options and poor
outcomes.
[9]
Many will develop resistance to
platinum-based chemotherapy, the backbone of first-line treatment,
underscoring the need for innovations that can deliver meaningful
benefit.
9
GSK in oncology
GSK is focused on developing differentiated medicines for cancers
where patients continue to face poor outcomes, treatment
resistance, limited options or significant treatment burden. We
focus where advances in science and technology offer the greatest
opportunity to improve outcomes across haematological, lung,
gastrointestinal, genitourinary and gynaecological cancers. Across
multiple modalities, including targeted small molecules,
antibody-drug conjugates (ADCs) and immunotherapies, GSK applies
deep expertise in cancer biology and immune system science to
develop differentiated medicines designed to deliver durable
responses, overcome resistance and reduce treatment
burden.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at
www.gsk.com
.
GSK enquiries
Media:
Tim
Foley
+44 (0)
20 8047 5502
(London)
Sarah
Clements
+44 (0)
20 8047 5502
(London)
Madison
Goring
+44 (0)
20 8047 5502
(London)
Kathleen
Quinn
+1 202
603 5003
(Washington
DC)
Alison
Hunt
+1 540
742 3391
(Washington
DC)
Investor
Relations:
James
Dodwell
+44 (0)
7881 269066
(London)
Mick
Readey
+44 (0)
7990 339653
(London)
Joanna
Tuplin
+44 (0)
7788 351650
(London)
Sam
Piper
+44 (0)
7824 525779
(London)
Dan
Smith
+44 (0)
7823 523885
(London)
Jeff
McLaughlin
+1 215
751 7002
(Philadelphia)
Frannie
DeFranco
+1 215
751 3126
(Philadelphia)
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the “Risk
Factors” section in GSK’s Annual Report on Form 20-F
for 2025, and GSK’s Q2 Results for 2026.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
References
[1]
Salutari V. Mocertatug rezetecan
(Mo-Rez) in patients with platinum-resistant ovarian cancer (PROC):
Updated results with longer follow-up from the global BEHOLD-1
study. Presented at the European Society for Medical Oncology
(ESMO) Congress 2026. October 2026.
[2]
Oaknin A, McKean W, van Dongen M, et
al. Mocertatug rezetecan (GSK5733584), a B7-H4 targeted antibody
drug conjugate, in platinum-resistant ovarian cancer and
endometrial cancer: First results from the global BEHOLD-1 study.
Presented at the Society of Gynecologic Oncology (SGO) Annual
Meeting on Women’s Cancer 2026. April
2026.
[3]
Lheureux S. BEHOLD-1: Exploratory
analysis of biomarkers associated with mocertatug rezetecan
(Mo-Rez) response in patients with platinum-resistant ovarian
cancer (PROC). Presented at the European Society for Medical
Oncology (ESMO) Congress 2026. October 2026.
[4]
Backes F. BEHOLD-Ovarian01: A Phase 3
randomised trial to evaluate mocertatug rezetecan (Mo-Rez) versus
standard of care (SoC) in patients (pts) with platinum-resistant
ovarian cancer (PROC). Presented at the European Society for
Medical Oncology (ESMO) Congress 2026. October
2026.
[5]
Oaknin A. BEHOLD-Endometrial01: A
randomised Phase 3 study evaluating the efficacy and safety of
mocertatug rezetecan (Mo-Rez) versus chemotherapy in patients with
advanced or recurrent endometrial cancer after platinum-based
therapy and immunotherapy. Presented at the European Society for
Medical Oncology (ESMO) Congress 2026. October
2026.
[6]
Ren Y, Xu R, Wang Y, et al. Global,
regional, and national burden of ovarian cancer in women aged
45 + from 1990 to 2021 and projections for 2050: a
systematic analysis based on the 2021 global burden of disease
study. J Cancer Res Clin Oncol.
2025;151(8):225.
[7]
Rauh-Hain JA, Krivak TC, Del Carmen
MG, Olawaiye AB. Ovarian cancer screening and early detection in
the general population. Rev Obstet Gynecol.
2011;4(1):15-21.
[8]
Salas Bolívar P, Gonzalez-Benitez
C, Carbonell López M, et al. Prognostic factors after the
first recurrence of ovarian cancer. Journal of Clinical Medicine.
2025;14(2):470.
[9]
Eskander RN, Moore KN, Monk BJ, et al.
Overcoming the challenges of drug development in platinum-resistant
ovarian cancer. Front Oncol. 2023;13:1258228.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
GSK plc
(Registrant)
Date: October
26, 2026
By:/s/ VICTORIA
WHYTE
--------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GSK plc
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
3fb84b633f· 2026-10-26 18:35 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前